GlassScriptPhysician profile
Olga Gonzalez-Byrne
NPI 1336516582
$4,093.90
in general payments reported to CMS, 2019-2025
22 companies · $877 in 2025
The $877 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,278 · 2022: $559 · 2023: $839 · 2024: $541 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,256.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $876.78 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $638.82 | 2021-2023 | Bexsero, Pediarix |
| Teva Pharmaceuticals USA, INC. | $422.60 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $328.05 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $239.32 | 2025 | Cobenfy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.17 | 2021-2022 | |
| Axsome Therapeutics, INC. | $208.98 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $162.67 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $135.50 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $125.00 | 2025 | Qelbree |
| Corium, LLC | $113.96 | 2023 | Azstarys |
| Redhill Biopharma INC. | $94.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $86.19 | 2021-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Abbvie INC. | $85.09 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $70.82 | 2021-2022 | |
| Pfizer INC. | $51.72 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $44.32 | 2023 | Ingrezza |
| Althera Pharmaceuticals LLC | $42.01 | 2021-2022 | |
| Kaleo, INC. | $14.25 | 2022 | |
| Amarin Pharma, INC. | $11.79 | 2022 | |
| Next Science LLC | $6.47 | 2023 | Xperience, Blastx, Surgx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Gonzalez-Byrne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.